Heterogeneity and Similarities in GLP-1 Receptor Agonist Cardiovascular Outcomes Trials

ELIXA was the only GLP-1RA CVOT that failed to show any CV benefit over usual care. In LEADER, SUSTAIN-6, HARMONY Outcomes, and REWIND, GLP-1RA showed statistical superiority on MACEs compared to usual care, while EXSCEL (P=0.06) just grazed it and PIONEER 6 showed a nonsignificant 21% reduction (P=0.17). However, SUSTAIN-6 lacked a prespecified analysis for superiority. Dulaglutide significantly decreased the incidence of MACEs by 12% in a...